209 related articles for article (PubMed ID: 37468280)
21. Neurofibromatosis type 2.
Uppal S; Coatesworth AP
Int J Clin Pract; 2003 Oct; 57(8):698-703. PubMed ID: 14627181
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis-related tumors: emerging biology and therapies.
Karajannis MA; Ferner RE
Curr Opin Pediatr; 2015 Feb; 27(1):26-33. PubMed ID: 25490687
[TBL] [Abstract][Full Text] [Related]
23. Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.
Dinh CT; Nisenbaum E; Chyou D; Misztal C; Yan D; Mittal R; Young J; Tekin M; Telischi F; Fernandez-Valle C; Liu XZ
Otol Neurotol; 2020 Jun; 41(5):e529-e537. PubMed ID: 32150022
[TBL] [Abstract][Full Text] [Related]
24. [Type 2 neurofibromatosis: intergenerational differences in genetic and clinical expression].
Drouet A; Le Moigne F; Salamé D; Quesnel L; Motolese C; des Portes V; Guilloton L; Pinson S
Arch Pediatr; 2014 Nov; 21(11):1233-40. PubMed ID: 25439059
[TBL] [Abstract][Full Text] [Related]
25. [Neurofibromatosis type 2 (NF2)].
Araki N; Takeshima H; Saya H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 2.
Evans DG; Sainio M; Baser ME
J Med Genet; 2000 Dec; 37(12):897-904. PubMed ID: 11106352
[TBL] [Abstract][Full Text] [Related]
27. Somatic Mosaicism of NF2 Gene Mutation with Constitutional NF1 Gene Mutation in Neurofibromatosis Type 2: a Case Report.
Yoo SJ; Hwang YS
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180429
[TBL] [Abstract][Full Text] [Related]
28. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract][Full Text] [Related]
29. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
30. Novel neurofibromatosis type 2 mutation presenting with status epilepticus.
DiFrancesco JC; Sestini R; Cossu F; Bolognesi M; Sala E; Mariani S; Saracchi E; Papi L; Ferrarese C
Epileptic Disord; 2014 Mar; 16(1):132-7. PubMed ID: 24667735
[TBL] [Abstract][Full Text] [Related]
31. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
[TBL] [Abstract][Full Text] [Related]
32. Magic but treatable? Tumours due to loss of merlin.
Hanemann CO
Brain; 2008 Mar; 131(Pt 3):606-15. PubMed ID: 17940085
[TBL] [Abstract][Full Text] [Related]
33. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
34. Prediction and evaluation of deleterious and disease causing non-synonymous SNPs (nsSNPs) in human NF2 gene responsible for neurofibromatosis type 2 (NF2).
Havranek B; Islam SM
J Biomol Struct Dyn; 2021 Nov; 39(18):7044-7055. PubMed ID: 32787631
[TBL] [Abstract][Full Text] [Related]
35. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
Blakeley J
Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
[TBL] [Abstract][Full Text] [Related]
36. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.
Kluwe L; Mautner V; Heinrich B; Dezube R; Jacoby LB; Friedrich RE; MacCollin M
J Med Genet; 2003 Feb; 40(2):109-14. PubMed ID: 12566519
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
38. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Blakeley JO; Evans DG; Adler J; Brackmann D; Chen R; Ferner RE; Hanemann CO; Harris G; Huson SM; Jacob A; Kalamarides M; Karajannis MA; Korf BR; Mautner VF; McClatchey AI; Miao H; Plotkin SR; Slattery W; Stemmer-Rachamimov AO; Welling DB; Wen PY; Widemann B; Hunter-Schaedle K; Giovannini M
Am J Med Genet A; 2012 Jan; 158A(1):24-41. PubMed ID: 22140088
[TBL] [Abstract][Full Text] [Related]
39. Role of NF2 haploinsufficiency in NF2-associated polyneuropathy.
Hanemann CO; Diebold R; Kaufmann D
Brain Pathol; 2007 Oct; 17(4):371-6. PubMed ID: 17655741
[TBL] [Abstract][Full Text] [Related]
40. Neurofibromatosis 2.
Baser ME; R Evans DG; Gutmann DH
Curr Opin Neurol; 2003 Feb; 16(1):27-33. PubMed ID: 12544854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
